泊沙康唑与脂质体两性霉素B在儿童及年轻成人血液肿瘤人群中预防侵袭性真菌感染的疗效与安全性
意大利帕多瓦大学医院血液肿瘤儿科中心的队列研究,纳入2017年1月至2022年3月接受泊沙康唑或脂质体两性霉素B(5 mg/kg每周两次)初级预防的3月龄至21岁患者,泊沙康唑组51例、脂质体两性霉素B组37例。泊沙康唑组不良事件发生率低于脂质体两性霉素B组,两组突破性侵袭性真菌感染事件相似,泊沙康唑可作为初级预防的可行替代方案。
要点
- 脂质体两性霉素B组不良事件发生率26%,泊沙康唑组5.6%。
- 两组突破性侵袭性真菌感染事件各4例,疗效相似。
- 泊沙康唑组不良事件风险较脂质体两性霉素B组低91%(HR 0.07,P < 0.001)。
核心结论
- 泊沙康唑与脂质体两性霉素B相比不良事件更少,两者预防突破性侵袭性真菌感染的疗效相似,泊沙康唑可作为初级预防的可行替代方案。
研究设计与样本
- 意大利帕多瓦大学医院血液肿瘤儿科中心的队列研究,纳入2017年1月至2022年3月接受泊沙康唑或脂质体两性霉素B(5 mg/kg每周两次)预防的3月龄至21岁患者,泊沙康唑组51例、脂质体两性霉素B组37例。
主要发现
- 不良事件发生率脂质体两性霉素B组为26%,泊沙康唑组为5.6%。
- 突破性侵袭性真菌感染事件两组相似,各4例。
- 急性淋巴细胞白血病患者中,脂质体两性霉素B组41%发生不良事件,泊沙康唑组为5%。
- 1年后不良事件概率泊沙康唑组较低(54% vs 65%,P < 0.001)。
- 总体泊沙康唑与不良事件风险降低91%相关(HR 0.07,P < 0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prevention of invasive fungal infections (IFIs) is crucial for paediatric haemato-oncological patients. This study evaluates the clinical efficacy and side-effects of posaconazole and liposomal amphotericin B (L-AmB) as primary prophylaxis. MATERIALS AND METHODS: This cohort study included patients aged 3 months to 21 years who received posaconazole or L-AmB (5 mg/kg twice weekly) as prophylaxis from January 2017 to March 2022 at the Hemato-oncological Pediatric Unit, University Hospital of Padua, Italy. Outcomes included adverse events and IFI diagnoses after the start of prophylaxis. Separate analyses were performed for patients with ALL and non-ALL diagnoses, and high-risk and low-risk groups. Cumulative incidence was calculated using the Kaplan-Meier estimator, with significant differences assessed using the log-rank test. Hazard ratios (HR) were estimated using Cox regression. RESULTS: Fifty-one patients received posaconazole, and 37 received L-AmB. Adverse events occurred in 26% of L-AmB patients and 5.6% of posaconazole patients. IFI breakthrough events were similar in both groups (four events each). In ALL patients, 41% experienced adverse events with L-AmB, compared to 5% with posaconazole. After 1 year, the probability of adverse events was lower in the posaconazole group (54% versus 65%, P < 0.001). Overall, posaconazole was associated with a 91% lower risk of adverse events (HR: 0.07, P < 0.001). Among high-risk patients, IFI breakthrough rates were similar between groups (P = 0.964). CONCLUSIONS: Posaconazole was associated with fewer adverse events than L-AmB, and both drugs showed similar efficacy in preventing IFI breakthroughs, making posaconazole a viable alternative for primary prophylaxis.
引用
- Chiusaroli L, Barbieri E, Dell'Anna L, et al. Efficacy and safety of posaconazole and liposomal amphotericin B use for prophylaxis of invasive fungal infections in a paediatric and young adult haemato-oncological population. J Antimicrob Chemother. 2025. PMID: 39792039. doi:10.1093/jac/dkae479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。